Figure 4 | Oncogene

Figure 4

From: The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272

Figure 4

Inhibition of oncogenic signaling pathways by HKI-272 in ERBB2-amplified and ERBB2-mutated NSCLC cells. Exponentially growing Calu-3 and H-1781 cells were starved for 2.5 h in the presence of HKI-272 or erlotinib and then stimulated with 100 ng/ml EGF for 1 h in the continued presence of drug. Lysates were subjected to Western blotting with the indicated antibodies. Tubulin was analysed as a loading control.

Back to article page